Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.74 |
| ▸ | CA12 | O43570 | 3/20 | 0.62 |
| ▸ | CA1 | P00915 | 3/20 | 0.62 |
| ▸ | CA2 | P00918 | 3/20 | 0.62 |
| ▸ | CA9 | Q16790 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | ABL1 | P00519 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | IDE | P14735 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | PLCD1 | P51178 | 1/20 | 0.60 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.57 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.57 |
| ▸ | HLCS | P50747 | 1/20 | 0.57 |
| ▸ | F2 | P00734 | 1/20 | 0.57 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13049579 | 1.00 | TDP1 (0.74) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL316398 | 1.00 | TDP1 (0.74) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL10308271 | 1.00 | TDP1 (0.74) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL13065003 | 1.00 | TDP1 (0.74) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL9733492 | 1.00 | TDP1 (0.74) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL288457 | 1.00 | TDP1 (0.74) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL20375017 | 1.00 | TDP1 (0.74) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL10140226 | 1.00 | TDP1 (0.74) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL20483620 | 1.00 | TDP1 (0.74) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL8083249 | 1.00 | TDP1 (0.74) | TDP1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411809-B1 | LUMINESCENCE ASSAY METHOD | OY ARCTIC PARTNERS AB (FI) | 2017-05-10 | — | — | EP | disclosed |
| US-8993246-B2 | Luminescence assay method | OY ARCTIC PARTNERS AB (FI) | 2015-03-31 | — | — | US | disclosed |
| US-20070207971-A1 | Neuraminidase inhibitor | ACADEMIA SINICA (TW) | 2007-09-06 | — | — | US | disclosed |
| US-20070207971-A1 | Neuraminidase inhibitor | ACADEMIA SINICA (TW) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070207971-A1 | Neuraminidase inhibitor | NEU1, NEU2, NEU4 | TDP1 2186/4885CA12 198/4885CA1 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.